Aclaris Therapeutics’ A-101 45% Topical Solution meets primary and all secondary endpoints in two Phase 2 clinical trials for common warts. Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced positive results from its two Phase 2 clinical…